Vaccines and Therapeutics Against Hantaviruses

Rongrong Liu; Hongwei Ma; Jiayi Shu; Qiang Zhang; Mingwei Han; Ziyu Liu; Xia Jin; Fanglin Zhang; Xingan Wu

doi:10.3389/fmicb.2019.02989

Vaccines and Therapeutics Against Hantaviruses

Front Microbiol. 2020 Jan 30:10:2989. doi: 10.3389/fmicb.2019.02989. eCollection 2019.

Authors

Rongrong Liu¹, Hongwei Ma¹, Jiayi Shu^{2

3}, Qiang Zhang⁴, Mingwei Han⁵, Ziyu Liu¹, Xia Jin², Fanglin Zhang¹, Xingan Wu¹

Affiliations

¹ Department of Microbiology, School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
² Scientific Research Center, Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Key Laboratory of Medical Molecular Virology of Ministry of Education & Health, Shanghai Medical College, Fudan University, Shanghai, China.
³ Viral Disease and Vaccine Translational Research Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
⁴ School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China.
⁵ Cadet Brigade, School of Basic Medicine, Fourth Military Medical University, Xi'an, China.

Abstract

Hantaviruses (HVs) are rodent-transmitted viruses that can cause hantavirus cardiopulmonary syndrome (HCPS) in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Eurasia. Together, these viruses have annually caused approximately 200,000 human infections worldwide in recent years, with a case fatality rate of 5-15% for HFRS and up to 40% for HCPS. There is currently no effective treatment available for either HFRS or HCPS. Only whole virus inactivated vaccines against HTNV or SEOV are licensed for use in the Republic of Korea and China, but the protective efficacies of these vaccines are uncertain. To a large extent, the immune correlates of protection against hantavirus are not known. In this review, we summarized the epidemiology, virology, and pathogenesis of four HFRS-causing viruses, HTNV, SEOV, PUUV, and DOBV, and two HCPS-causing viruses, ANDV and SNV, and then discussed the existing knowledge on vaccines and therapeutics against these diseases. We think that this information will shed light on the rational development of new vaccines and treatments.

Keywords: HFRS; HPCS; hantavirus; therapeutic strategies; vaccine.

Publication types

Review